Reviva Pharmaceuticals to Participate in the Lytham Partners Fall 2024 Investor Conference
Reviva Pharmaceuticals Holdings (NASDAQ: RVPH), a late-stage pharmaceutical company, announced its participation in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024. The company's Founder, President, and CEO, Laxminarayan Bhat, Ph.D., will deliver a webcasted presentation at 3:30 p.m. ET and host one-on-one meetings with investors.
The virtual event will be accessible through various platforms, including the conference registration page, Lytham Partners' conference home page, and Reviva's website. Investors can arrange meetings with management by contacting Lytham Partners or registering for the event online.
Reviva focuses on developing therapies for central nervous system (CNS), inflammatory, and cardiometabolic diseases, addressing unmet medical needs in these areas.
Reviva Pharmaceuticals Holdings (NASDAQ: RVPH), un'azienda farmaceutica in fase avanzata, ha annunciato la sua partecipazione alla Lytham Partners Fall 2024 Investor Conference il 1 ottobre 2024. Il fondatore, presidente e CEO dell'azienda, Laxminarayan Bhat, Ph.D., presenterà una relazione in webcast alle 15:30 ET e ospiterà incontri individuali con gli investitori.
L'evento virtuale sarà accessibile attraverso diverse piattaforme, inclusa la pagina di registrazione della conferenza, la home page della conferenza di Lytham Partners e il sito web di Reviva. Gli investitori possono organizzare incontri con il management contattando Lytham Partners o registrandosi online per l'evento.
Reviva si concentra sullo sviluppo di terapie per malattie del sistema nervoso centrale (CNS), infiammatorie e cardiometaboliche, affrontando bisogni medici non soddisfatti in queste aree.
Reviva Pharmaceuticals Holdings (NASDAQ: RVPH), una compañía farmacéutica en etapa avanzada, anunció su participación en la Lytham Partners Fall 2024 Investor Conference el 1 de octubre de 2024. El fundador, presidente y CEO de la empresa, Laxminarayan Bhat, Ph.D., ofrecerá una presentación transmitida por webcast a las 3:30 p.m. ET y llevará a cabo reuniones individuales con inversores.
El evento virtual será accesible a través de varias plataformas, incluida la página de registro de la conferencia, la página principal de la conferencia de Lytham Partners y el sitio web de Reviva. Los inversores pueden organizar reuniones con la dirección contactando a Lytham Partners o registrándose en línea para el evento.
Reviva se enfoca en desarrollar terapias para enfermedades del sistema nervioso central (CNS), inflamatorias y cardiometabólicas, abordando necesidades médicas insatisfechas en estas áreas.
Reviva Pharmaceuticals Holdings (NASDAQ: RVPH), 후기단계 제약회사,가 2024년 10월 1일에 Lytham Partners Fall 2024 Investor Conference에 참여한다고 발표했습니다. 회사의 창립자이자 회장, CEO인 Laxminarayan Bhat, Ph.D.가 동부 표준시 기준으로 오후 3시 30분에 웹캐스트 발표를 진행하며, 투자자들과의 1대 1 미팅을 개최할 예정입니다.
이번 가상 행사에는 컨퍼런스 등록 페이지, Lytham Partners의 컨퍼런스 홈페이지, Reviva의 웹사이트 등 다양한 플랫폼을 통해 접속할 수 있습니다. 투자자들은 Lytham Partners에 연락하거나 온라인으로 행사에 등록하여 경영진과의 미팅을 조율할 수 있습니다.
Reviva는 중추신경계(CNS), 염증성 및 심혈관대사 질환에 대한 치료제를 개발하는 데 집중하고 있으며, 이러한 분야의 충족되지 않은 의료 필요를 해결하고 있습니다.
Reviva Pharmaceuticals Holdings (NASDAQ: RVPH), une entreprise pharmaceutique en phase avancée, a annoncé sa participation à la Lytham Partners Fall 2024 Investor Conference le 1er octobre 2024. Le fondateur, président et PDG de l'entreprise, Laxminarayan Bhat, Ph.D., présentera une conférence en webdiffusion à 15h30 ET et animera des réunions individuelles avec les investisseurs.
L'événement virtuel sera accessible via diverses plateformes, y compris la page d'inscription à la conférence, la page d'accueil de la conférence Lytham Partners et le site web de Reviva. Les investisseurs peuvent organiser des réunions avec la direction en contactant Lytham Partners ou en s'inscrivant en ligne pour l'événement.
Reviva se concentre sur le développement de thérapies pour les maladies du système nerveux central (SNC), inflammatoires et cardiométaboliques, répondant ainsi à des besoins médicaux non satisfaits dans ces domaines.
Reviva Pharmaceuticals Holdings (NASDAQ: RVPH), ein pharmazeutisches Unternehmen in der späten Entwicklungsphase, hat seine Teilnahme an der Lytham Partners Fall 2024 Investor Conference am 1. Oktober 2024 angekündigt. Der Gründer, Präsident und CEO des Unternehmens, Laxminarayan Bhat, Ph.D., wird um 15:30 Uhr ET eine Präsentation per Webcast halten und Einzelgespräche mit Investoren führen.
Die virtuelle Veranstaltung wird über verschiedene Plattformen zugänglich sein, einschließlich der Registrierungsseite der Konferenz, der Startseite der Lytham Partners-Konferenz und der Website von Reviva. Investoren können Meetings mit dem Management vereinbaren, indem sie Lytham Partners kontaktieren oder sich online für die Veranstaltung registrieren.
Reviva konzentriert sich auf die Entwicklung von Therapien für Erkrankungen des zentralen Nervensystems (ZNS), entzündliche und kardiometabolische Krankheiten und deckt damit unerfüllte medizinische Bedürfnisse in diesen Bereichen ab.
- None.
- None.
CUPERTINO, Calif., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in a webcasted presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2024 Investor Conference, taking place virtually on Tuesday, October 1, 2024.
Company Webcast
The webcasted presentation will take place at 3:30 p.m. ET on Tuesday, October 1, 2024. The webcast can be accessed by visiting the conference registration at https://app.webinar.net/Xokw4go4qvO. The webcast can also be accessed by visiting the conference home page at https://lythampartners.com/fall2024 or on the Company’s website at https://revivapharma.com. The webcast will also be available for replay following the event.
1×1 Meetings
Management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at 1x1@lythampartners.com or register for the event at https://lythampartners.com/fall2024invreg.
About Reviva
Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva’s current pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic diseases. Reviva’s pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries.
Corporate Contact:
Reviva Pharmaceuticals Holdings, Inc.
Laxminarayan Bhat, PhD
www.revivapharma.com
Investor Relations Contact:
LifeSci Advisors, LLC
Bruce Mackle
bmackle@lifesciadvisors.com
FAQ
When is Reviva Pharmaceuticals (RVPH) participating in the Lytham Partners Fall 2024 Investor Conference?
What time is Reviva Pharmaceuticals' (RVPH) webcasted presentation at the Lytham Partners conference?
How can investors access Reviva Pharmaceuticals' (RVPH) presentation at the Lytham Partners conference?
What therapeutic areas does Reviva Pharmaceuticals (RVPH) focus on?
How can investors arrange one-on-one meetings with Reviva Pharmaceuticals (RVPH) management at the Lytham Partners conference?
